Ravenel Boykin Curry IV
Eagle Capital Management
Eagle Capital Management Valeant Pharmaceuticals International Inc stake
total: 177
Eagle Capital Management VRX trades
- Total transactions:
- 12
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 8
- Held since:
- 2014 Q2
- Held for:
- 13 quarters
- Latest activity:
- 2017 Q3
According to 2026 Q2 report, Eagle Capital Management doesn't hold any Valeant Pharmaceuticals International Inc (VRX) shares. To date, the estimated cost basis is nearly $114.42 for "buy" trades and estimated average "sell" price is $34.91. Eagle Capital Management first purchased VRX in 2014 Q2, initially acquiring about 3.77M shares. Since the initial investment in Valeant Pharmaceuticals International Inc (VRX), Eagle Capital Management has made 11 more transactions.
When did Eagle Capital Management sell Valeant Pharmaceuticals International Inc (VRX)?
Eagle Capital Management sold off the entire Valeant Pharmaceuticals International Inc (VRX) position in 2017 Q3.
When did Eagle Capital Management buy Valeant Pharmaceuticals International Inc (VRX)?
Eagle Capital Management first invested in Valeant Pharmaceuticals International Inc (VRX) in 2014 Q2 at the reported quarter-end price of $126.12 per share.
What's the cost basis of Eagle Capital Management's VRX stake?
The estimated cost basis for Valeant Pharmaceuticals International Inc (VRX) stake is around $114.42 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $114.42
- Weighted AVG sell price:
- $34.90
Eagle Capital Management's historical trades in Valeant Pharmaceuticals International Inc
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2017 Q3
|
0.00%
|
$17.28
|
-100% (-15,918)
|
|||
|
2016 Q4
|
0.00%
|
$14.51
|
-45.40% (-13,235)
|
|||
|
2016 Q3
|
0.00%
|
$24.56
|
-6.72% (-2,100)
|
|||
|
2016 Q2
|
0.00%
|
$20.13
|
-99.47% (-5,867,292)
|
|||
|
2016 Q1
|
0.65%
|
$26.30
|
-16.14% (-1,135,554)
|
|||
|
2015 Q4
|
2.92%
|
$101.65
|
+108.43% (+3,659,378)
|
|||
|
2015 Q3
|
2.64%
|
$178.38
|
-1.37% (-46,855)
|
|||
|
2015 Q2
|
2.99%
|
$222.15
|
-9.52% (-359,951)
|
|||
|
2015 Q1
|
2.79%
|
$198.62
|
-3.39% (-132,555)
|
|||
|
2014 Q4
|
2.11%
|
$143.11
|
-0.29% (-11,392)
|
|||
|
2014 Q3
|
1.99%
|
$131.20
|
+4.13% (+155,823)
|
|||
|
2014 Q2
|
1.88%
|
$126.12
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.